secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001601830-24-000110
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion announces Roche exercises option for first Neuroscience Phenomap; receives $30M fee
--------------------------------------------------------------------------------

- Roche exercised option for first Neuroscience Phenomap under 2021 Collaboration Agreement.
- Recursion to receive $30 million Acceptance Fee from Roche.
- Option exercised by Genentech, a member of the Roche Group.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000110/0001601830-24-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000110/rxrx-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer